Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Liu, Lei ^a   Chen, Long ^a   Luo, Yan ^a   Chen, Wenxing ^a   Zhou, Hongyu ^a   Xu, Baoshan ^a   Han, Xiuzhen ^a   Shen, Tao ^a   Huang, Shile ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; RAPAMYCIN; SOMATOMEDIN C;

ARTICLE; CELL MOTILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EWING SARCOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN TARGETING; RHABDOMYOSARCOMA;

CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; GENES, DOMINANT; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE KINASE 1; OKADAIC ACID; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EUKARYOTA; MAMMALIA;

EID: 77956500306     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010578     Document Type: Article

References (54)

1. Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318.
2. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, et al. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189.
3. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
4. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, et al. (2003) GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrientsensitive interaction between raptor and mTOR. Mol Cell 11: 895-904.
5. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, et al. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10: 457-468.
6. Fonseca BD, Smith EM, Lee VH, Mackintosh C, Proud CG (2007) PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 282: 24514-24524.
7. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, et al. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903-915.
8. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9: 316-323.
9. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, et al. (2006) mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16: 1865-1870.
10. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128.
11. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptorindependent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302.
12. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, et al. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137.
13. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, et al. (2007) Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 405: 513-522.
14. Yang Q, Inoki K, Ikenoue T, Guan KL (2006) Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20: 2820-2832.
15. Woo SY, Kim DH, Jun CB, Kim YM, Haar EV, Lee SI, et al. (2007) PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J Biol Chem 282: 25604-25612.
16. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
17. García-Martínez JM, Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoidinduced protein kinase 1 (SGK1). Biochem J 416: 375-385.
18. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, et al. (2008) mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30: 701-711.
19. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, et al. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886.
20. Fasolo A, Sessa C (2008) mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 17: 1717-1734.
21. Sakakibara K, Liu B, Hollenbeck S, Kent KC (2005) Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am J Physiol Heart Circ Physiol 288: H2861-2868.
22. Rhoads JM, Niu X, Odle J, Graves LM (2006) Role of mTOR signaling in intestinal cell migration. Am J Physiol Gastrointest Liver Physiol 291: G510-517.
23. Liu L, Li F, Cardelli JA, Martin KA, Blenis J, et al. (2006) Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 25: 7029-7040.
24. Liu L, Chen L, Chung J, Huang S (2008) Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 27: 4998-5010.
25. Hernández-Negrete I, Carretero-Ortega J, Rosenfeldt H, Hernández-García R, Calderón-Salinas JV, et al. (2007) P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J Biol Chem 282: 23708-23715.
26. Dada S, Demartines N, Dormond O (2008) mTORC2 regulates PGE2- mediated endothelial cell survival and migration. Biochem Biophys Res Commun 372: 875-879.
27. Janssens V, Goris J, Van Hoof C (2005) PP2A: the expected tumor suppressor. Curr Opin Genet Dev 15: 34-41.
28. Peterson RT, Desai BN, Hardwick JS, Schreiber SL (1999) Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci USA 96: 4438-4442.
29. Murata K, Wu J, Brautigan DL (1997) B cell receptor-associated protein alpha4 displays rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A. Proc Natl Acad Sci USA 94: 10624-10629.
30. Di Como CJ, Arndt KT (1996) Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. Genes Dev 10: 1904-1916.
31. Chen J, Peterson RT, Schreiber SL (1998) Alpha 4 associates with protein phosphatases 2A, 4, and 6. Biochem Biophys Res Commun 247: 827-832.
32. Nanahoshi M, Nishiuma T, Tsujishita Y, Hara K, Inui S, et al. (1998) Regulation of protein phosphatase 2A catalytic activity by alpha4 protein and its yeast homolog Tap42. Biochem Biophys Res Commun 251: 520-526.
33. Jiang Y, Broach JR (1999) Tor proteins and protein phosphatase 2A reciprocally regulate Tap42 in controlling cell growth in yeast. EMBO J 18: 2782-2792.
34. Kloeker S, Reed R, McConnell JL, Chang D, Tran K, et al. (2003) Parallel purification of three catalytic subunits of the protein serine/threonine phosphatase 2A family (PP2A(C), PP4(C), and PP6(C)) and analysis of the interaction of PP2A(C) with alpha4 protein. Protein Expr Purif 31: 19-33.
35. Nien WL, Dauphinee SM, Moffat LD, Too CKL (2007) Overexpression of the mTOR alpha4 phosphoprotein activates protein phosphatase 2A and increases Stat1alpha binding to PIAS1. Mol Cell Endocrinol 263: 10-17.
36. Inui S, Sanjo H, Maeda K, Yamamoto H, Miyamoto E, et al. (1998) Ig receptor binding protein 1 (alpha4) is associated with a rapamycin-sensitive signal transduction in lymphocytes through direct binding to the catalytic subunit of protein phosphatase 2A. Blood 92: 539-546.
37. Parameswaran N, Nambi P, Hall CS, Brooks DP, Spielman WS (2000) Adrenomedullin decreases extracellular signal-regulated kinase activity through an increase in protein phosphatase-2A activity in mesangial cells. Eur J Pharmacol 388: 133-138.
38. Pullar CE, Chen J, Isseroff RR (2003) PP2A activation by b2-adrenergic receptor agonists: novel regulatory mechanism of keratinocyte migration. J Biol Chem 278: 22555-22562.
39. Gendron S, Couture J, Aoudjit F (2003) Integrin alpha2beta1 inhibits Fasmediated apoptosis in T lymphocytes by protein phosphatase 2A-dependent activation of the MAPK/ERK pathway. J Biol Chem 278: 48633-48643.
40. O'Connor R (2003) Regulation of IGF-I receptor signaling in tumor cells. Horm Metab Res 35: 771-777.
41. Jackson JL, Young MR (2003) Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants. Clin Exp Metastasis 20: 357-364.
42. Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, et al. (1999) Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59: 886-894.
43. Beevers CS, Chen L, Liu L, Luo Y, Webster NJ, et al. (2009) Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res 69: 1000-1008.
44. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, et al. (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970.
45. Hardie DG, Haystead TA, Sim AT (1991) Use of okadaic acid to inhibit protein phosphatases in intact cells. Methods Enzymol 201: 469-476.
46. Harwood FC, Shu L, Houghton PJ (2008) mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A. J Biol Chem 283: 2575-2585.
47. Evans DR, Myles T, Hofsteenge J, Hemmings BA (1999) Functional expression of human PP2Ac in yeast permits the identification of novel C-terminal and dominant-negative mutant forms. J Biol Chem 274: 24038-24046.
48. Erbay E, Park IH, Nuzzi PD, Schoenherr CJ, Chen J (2003) IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients. J Cell Biol 163: 931-936.
49. Erbay E, Chen J (2001) The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism. J Biol Chem 276: 36079-36082.
50. Shu L, Zhang X, Houghton PJ (2002) Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin. J Biol Chem 277: 16726-16732.
51. Ugi S, Imamura T, Ricketts W, Olefsky JM (2002) Protein phosphatase 2A forms a molecular complex with Shc and regulates Shc tyrosine phosphorylation and downstream mitogenic signaling. Mol Cell Biol 22: 2375-2387.
52. Yumoto N, Yu X, Hatakeyama M (2006) Expression of the ErbB4 receptor causes reversal regulation of PP2A in the Shc signal transduction pathway in human cancer cells. Mol Cell Biochem 285: 165-171.
53. Huang S, Shu L, Dilling MB, Easton J, Harwood FC, et al. (2003) Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21Cip1. Mol Cell 11: 1491-1501.
54. Huang S, Shu L, Easton J, Harwood FC, Germain GS, et al. (2004) Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem 279: 36490-36496.